Cargando…

Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study

OBJECTIVE: The management experience for plasma cell leukemia (PCL) is still limited by PCL’s rare incidence and aggressive course. The goal of this study was to further identify the efficacy of bortezomib-containing regimens for PCL in Chinese patients. MATERIALS AND METHODS: In this study, 56 cons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Huijuan, Zhou, Huixing, Zhang, Zhiyao, Geng, Chuanying, Chen, Wenming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236418/ https://www.ncbi.nlm.nih.gov/pubmed/31769277 http://dx.doi.org/10.4274/tjh.galenos.2019.2019.0254

Ejemplares similares

The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma
por: Geng, Chuanying, et al.
Publicado: (2021)

Bortezomib-Based Regimens and Plasma Cell Leukemia
por: Bolaman, Ali Zahit
Publicado: (2021)

CD20 expression: A risk stratification factor for newly diagnosed multiple myeloma with t(11;14)
por: Jian, Yuan, et al.
Publicado: (2022)

Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation
por: Geng, Chuanying, et al.
Publicado: (2022)

Characteristics and Risk Factors of Ultra-High-Risk Patients with Newly Diagnosed Multiple Myeloma
por: Geng, Chuanying, et al.
Publicado: (2023)

Successful treatment with bortezomib-containing regimen of primary plasma cell leukemia: a case report
por: Obeidat, Mohammad Bader, et al.
Publicado: (2020)

Mechanisms underlying synergism between circularized tumor necrosis factor‐related apoptosis inducing ligand and bortezomib in bortezomib‐sensitive or ‐resistant myeloma cells
por: Leng, Yun, et al.
Publicado: (2022)

Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients
por: Jian, Yuan, et al.
Publicado: (2016)

Echocardiography‐defined pulmonary hypertension is an adverse prognostic factor for newly diagnosed multiple myeloma patients
por: Jian, Yuan, et al.
Publicado: (2022)

Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients
por: Wang, Hua, et al.
Publicado: (2016)

Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report
por: Chan, Steven M, et al.
Publicado: (2009)

Therapeutic effect of bortezomib for primary plasma cell leukemia followed by auto/allo stem cell transplantation
por: Ozasa, Ryotaro, et al.
Publicado: (2012)

Retrospective analysis of 264 multiple myeloma patients
por: GENG, CHUANYING, et al.
Publicado: (2013)

Bortezomib-induced diffuse alveolar hemorrhage in a patient with plasma cell leukemia
por: Wirth, Ingrid M., et al.
Publicado: (2020)

P961: BORTEZOMIB, RITUXIMAB AND DEXAMETHASONE REGIMEN (BDR) IN WALDENSTRÖM MACROGLOBULINEMIA: A RETROSPECTIVE ANALYSIS
por: Hueso, Thomas, et al.
Publicado: (2023)

Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
por: Robak, Paweł, et al.
Publicado: (2021)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

Relationship between bortezomib-containing regimens and the incidence of tuberculosis in patients with myeloma
por: Kim, Kihyun, et al.
Publicado: (2013)

Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients
por: Qian, Wensi, et al.
Publicado: (2020)

The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis
por: Lu, Jing, et al.
Publicado: (2015)

Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma
por: LIU, NIAN, et al.
Publicado: (2015)

Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients
por: Delforge, Michel, et al.
Publicado: (2022)

P21 EFFECTIVENESS AND SAFETY OF DELAYED BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) REGIMEN
por: Del Fabro, V., et al.
Publicado: (2023)

PB1852: AZACITIDINE COMBINED WITH HAG REGIMEN FOR ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA:PRIMARY ANALYSIS OF A RETROSPECTIVE COHORT
por: Zheng, W., et al.
Publicado: (2022)

Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells
por: Roeten, Margot S.F., et al.
Publicado: (2021)

Incidence and Risk Factors of Osteonecrosis of Femoral Head in Multiple Myeloma Patients Undergoing Dexamethasone-Based Regimens
por: Wu, Xinjie, et al.
Publicado: (2020)

Leukemia Cutis Associated with Secondary Plasma Cell Leukemia
por: DeMartinis, Nicole C, et al.
Publicado: (2017)

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
por: Lee, Se Ryeon, et al.
Publicado: (2010)

Monoclonal Gammopathy of Renal Significance: Clinical and Histological Efficacy of a Bortezomib-Based Regimen
por: Quattrocchio, Giacomo, et al.
Publicado: (2020)

Exonic variants in multiple myeloma patients associated with relapsed/ refractory and response to bortezomib regimens
por: Kakoo, Ashraf, et al.
Publicado: (2022)

Nursing management of treatment-related venous thromboembolism in patients with multiple myeloma
por: Yang, Bianhong, et al.
Publicado: (2023)

Treatment of Light Chain Deposition Disease Using Bortezomib-Based Regimen Followed by Thalidomide-Based Regimen in a Saudi Male
por: Adamu, Bappa, et al.
Publicado: (2016)

Two Secondary Primary Malignancies after Bortezomib Therapy for Multiple Myeloma: A Single-center Experience
por: Guo, Tian-Jiao, et al.
Publicado: (2017)

Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma
por: Lee, Won-Seop, et al.
Publicado: (2011)

Immunoglobulin D Multiple Myeloma, Plasma Cell Leukemia and Chronic Myelogenous Leukemia in a Single Patient Treated Simultaneously with Lenalidomide, Bortezomib, Dexamethasone and Imatinib
por: Ali, Naveed, et al.
Publicado: (2016)

Bortezomib
por: Rajappa, Senthil
Publicado: (2010)

Treatment and prognostic factors for survival in newly diagnosed multiple myeloma patients with bortezomib and dexamethasone regimen: a single Chinese center retrospective study
por: Chen, Runzhe, et al.
Publicado: (2017)

Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety
por: Zhai, Yujia, et al.
Publicado: (2021)

Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China
por: Yao, Rongxin, et al.
Publicado: (2019)

Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations
por: Liu, Jianhao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d2ba51t8voa269adfinq39gsnu